Baird analyst Joel Beatty reiterated an Outperform rating and $31.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst commented: "Acadia ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments